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Abstract
Background: Fabry disease is characterized by a progressive deposition of sphingolipids in different organ systems,
whereby cardiac involvement leads to death. We hypothesize that lysosomal storage of sphingolipids in the heart
as occurring in Fabry disease does not reflect in higher cardiac lipid concentrations detectable by 1H magnetic
resonance spectroscopy (MRS) at 3 Tesla.
Methods: Myocardial lipid content was quantified in vivo by 1H-MRS in 30 patients (12 male, 18 female; 18 patients
treated with enzyme replacement therapy) with genetically proven Fabry disease and in 30 healthy controls. The
study protocol combined 1H-MRS with cardiac cine imaging and LGE MRI in a single examination.
Results: Myocardial lipid content was not significantly elevated in Fabry disease (p = 0.225). Left ventricular (LV)
mass was significantly higher in patients suffering from Fabry disease compared to controls (p = 0.019). Comparison
of patients without signs of myocardial fibrosis in MRI (LGE negative; n = 12) to patients with signs of fibrosis (LGE
positive; n = 18) revealed similar myocardial lipid content in both groups (p > 0.05), while the latter showed a trend
towards elevated LV mass (p = 0.076).
Conclusions: This study demonstrates the potential of lipid metabolic investigation embedded in a comprehensive
examination of cardiac morphology and function in Fabry disease. There was no evidence that lysosomal storage of
sphingolipids influences cardiac lipid content as measured by 1H-MRS. Finally, the authors share the opinion that a
comprehensive cardiac examination including three subsections (LGE; 1H-MRS; T1 mapping), could hold the highest
potential for the final assessment of early and late myocardial changes in Fabry disease.
Keywords: Morbus Fabry, Magnetic resonance spectroscopy, Myocardial lipid content, Rare diseases, Lysosomal
storage disease, Late gadolinium enhancement
Background
Fabry-Anderson disease is a x-linked lysosomal storage
disease caused by a deficiency of the enzyme alpha-ga-
lactosidase A (α-Gal A; also termed ceramide trihexosi-
dase) [1]. As a consequence, the decreased or almost
absent enzymatic activity leads to progressive accumula-
tion and deposition of sphingolipids, mainly Globotriao-
sylceramide (also termed ceramide trihexoside), in
different organ systems [2]. The disease is pan ethnic
and incidence estimates ranges from about 1 in 40.000
up to 60.000 [1, 3]. Although the disease predominantly
affects males, it is now widely accepted that females - as
carriers of the disease - can also be affected to a mild or
even severe degree due to random X-chromosomal in-
activation [4, 5].
Cardiac involvement is crucial for morbidity and mor-
tality of the disease. Hallmarks of cardiac involvement in
Fabry disease are myocardial hypertrophy and fibrosis.
Both pathologies have been previously studied by mag-
netic resonance imaging, using cine- and late gadolinium
enhancement (LGE)- sequences [6–8].
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Several theories for the genesis of cardiac alterations
in Fabry disease are being discussed [9, 10]. It is widely
accepted that fibrosis is a key feature of Fabry disease.
Currently, late and secondary myocardial changes (e.g.
LGE or perfusion mismatch) are used to plan enzyme
replacement therapy (ERT) as the current cornerstone of
the therapeutic strategy in Fabry disease [9, 11, 12]. Add-
itionally, recent studies revealed the high potential of
noncontrast T1 mapping as a sensitive and specific car-
diovascular MRI parameter in patients with Fabry dis-
ease irrespective of sex, left ventricular (LV) morphology
and function [13, 14]. Another contributing factor might
be cardiac lipid storage, which can be found at different
locations in the heart: On the one hand there is intra-
myocardial triglyceride (TG) deposition, which is linked
to various pathological conditions (e.g. diabetes mellitus,
metabolic syndrome and obesity); on the other hand
there is a lysosomal storage of sphingolipids, especially
occurring in Fabry disease. Post-mortem studies, as well
as invasive myocardial biopsies have shown a ubiquitous
deposition of sphingolipids in the myocardium of pa-
tients suffering from cardiac Fabry disease [15].
Due to the fact that ERT is less efficacious when
initiated after the development of tissue injury [16], it
seems to be of utmost importance to identify potential
early predictors of myocardial involvement in Fabry dis-
ease, and thus allowing more accurate, respectively early
onset of ERT. Therefore, the direct measurement of
cardiac lipid deposition has been discussed as a future
concept [17]. The highly invasive tissue acquisition by
myocardial biopsy is naturally associated with a non-
negligible risk of complications in each individual patient
[18, 19]. In contrast, non-invasive assessment of myocar-
dial lipid depositions by localized 1H magnetic resonance
spectroscopy (1H-MRS) is a suitable and time-efficient
alternative [20]. In the last decade, several studies dem-
onstrated the potential of 1H-MRS at 1.5 Tesla (T) for
the non-invasive assessment of myocardial lipid content
[20–22]. However, results are still limited by the low sig-
nal/noise-ratio (SNR) of metabolite resonances at 1.5 T.
As the signal strength of all metabolites is proportional
to field strength, higher magnetic field strength enable
measurements of metabolite concentrations with higher
accuracy and without substantial changes of the noise
level [23, 24]. The increased availability of 3 T MR sys-
tems for clinical routine has opened the field for even
more precise non-invasive evaluation of myocardial
lipids. In the light of technical development, dual trig-
gered (ECG and respiration) 1H-MRS enables the use of
this technique for cardiac examinations [25].
We hypothesize that lysosomal storage of sphingoli-
pids as occurring in Fabry disease does not reflect in
higher cardiac lipid concentrations detectable by 1H-
MRS. Therefore the aim of this study was to non-
invasively evaluate myocardial lipid deposition in Fabry
disease with 1H-MRS at 3 T. We designed a one stop
cardiac examination to evaluate myocardial lipid content
in vivo, left ventricular mass and function, as well as
presence or absence of myocardial fibrosis. The study
protocol combined 1H-MR single voxel spectroscopy
with cardiac cine and late enhancement MRI in a single
examination.
Methods
A total of thirty consecutive patients (12 male, 18 fe-
male; mean age ± standard deviation (SD), 41.5 ±
13.5 years; range 17–68 years) with genetically proven
Fabry disease were included in the study over 24 months.
Any history of cardio-vascular disease, diabetes mellitus
and respectively any manifestations of an advanced
metabolic syndrome were exclusion criteria. 18 patients
were treated with ERT at the time of examination
(average time of ERT 6.2 years). Body mass index (BMI)
ranged between 17.5 and 38.7 kg/m2 (mean 24.5 ±
5.5 kg/m2).
Thirty healthy volunteers (22 male, 8 female; mean age
30.6 ± 7.7 years; range 24–48 years) without any history
of cardio-vascular or metabolic disease were recruited
for the control group. BMI varied between 16.0 and
33.5 kg/m2 (mean 22.4 ± 3.4 kg/m2) in the control group.
All participants had to comply with a fasting period of at
least 2 h before 1H-MRS.
All patients and volunteers were informed about the
research status of the study and signed their informed
consent. The study protocol was approved by the institu-
tional review board.
All cardiac imaging including 1H-MRS was acquired in
supine position. Double-triggered high-field cardiac 1H
MR-spectroscopy and MR-imaging were performed
using a 12–channel phased array coil on a 3 T MR scan-
ner (MAGNETOM® Trio, Siemens AG Healthcare
Sector, Erlangen, Germany). The time gap between intra-
venous contrast administration and LGE acquisition was
used to acquire the spectroscopic data in the patients
cohort. In the control group 1H-MRS and cardiac func-
tion data were also acquired but no intravenous contrast
medium was applied.
Cardiac MRI
Cine MRI of the short and long heart axis was per-
formed using a Steady-State Free Precession (SSFP) se-
quence (field of view [FOV] adjusted individually; matrix
size, 256 × 216; TE, 1.48 ms; TR, 3.5 ms; flip angle, 45°;
slice thickness, 8 mm; slice gap, 0.00 mm; temporal
resolution 46.9 ms). The LV mass and LV function,
expressed as ejection fraction (EF), were analysed as de-
scribed previously [6].
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In patients, LGE was obtained 12–15 min after intra-
venous injection of 0.2 mmol/kg Gadobutrol (Gadovist®,
Bayer HealthCare, Leverkusen, Germany). An inversion
recovery two-dimensional SSFP sequence (FOV adjusted
individually; matrix size, 204 × 256; TE, 1.2 ms; TR,
3.0 ms; time of inversion [TI] determined individually;
flip angle, 40°) was used nulling the signal of normal
myocardium [26]. The evaluation of LGE (presence or
absence) as a marker for myocardial fibrosis was per-
formed by two independent radiologists with extended
experience in the field.
Cardiac MRS
For data acquisition, a double-triggered single voxel
spin-echo spectroscopic sequence (PRESS) was applied
(TR of at least one heartbeat [typically one respiratory
cycle]; TE = 35 ms; 32 averages). The utilized sequence is
a WIP sequence of Siemens® (Siemens AG Healthcare
Sector) and not commercially available. Proton spectra
were collected from a 20 × 15 × 20 mm3 voxel which was
positioned within the interventricular septum on the
four-chamber and short-axis images, thereby avoiding
contamination by epicardial fat (Fig. 1a and b) [27]. For
respiratory motion gating a navigator was positioned on
the lung-liver interface of the right diaphragm [25].
Measurements were acquired at end-systole and end-
expiration. In all subjects, two consecutive 1H MR spec-
tra (with and without water suppression) were acquired.
As the water signal (set as reference to 4.7 ppm) is the
most prominent peak in non-water suppressed spectra
(Fig. 2a), the quantification of resonance signals arising
from CH2 (methylene groups) and CH3 (methyl groups)
is limited by the digital resolution. The resonance signals
of interest become the most prominent peaks in water
suppressed spectra. Thus, quantification is more reliable
in these data sets. The acquired 1H MR spectra with
suppression of the water signal revealed the expected
resonances for intramyocardial lipids at 1.3 ppm for
methylene groups, respectively 0.9 ppm for methyl
groups (Fig. 2b).
A vendor specific software (Siemens Sector Healthcare,
Erlangen, Germany) was used for post-processing of 1H-
MRS data. In both types of spectra, post-processing was
applied with a Hanning apodization of 300 ms and auto-
matic frequency shift correction. Determination of inte-
gral values for the resonance signals was supported by
prior knowledge. The water signal was set to a ∂-value
of 4.7 ppm, which caused protons in methylene (CH2)
groups to appear at 1.3 ppm, as well as protons in me-
thyl (CH3) groups at 0.9 ppm [28]. The total myocardial
lipid content resulted from the addition of the area of
the resonance signal of both peaks and was expressed as
lipid/water resonance ratio (%).
Statistical data analysis
Normal distribution of our data was evaluated by the
Kolmogorov-Smirnov test and the Shapiro-Wilk test. As
EF and LV mass proved to be normally distributed, an
independent T-test was used for evaluation, while the
Mann-Whitney-U-Test was utilized for evaluation of the
non-normally distributed myocardial lipid content to
check for statistical significance. A value of p < 0.05 was
considered significant. Statistical analyses were per-
formed by using statistical software (IBM SPSS Statistics
for Mac, Version 21.0, Armonk, NY, USA).
Results
Patients cohort – control group
Gender and age-specific attributes, as well as clinical
and laboratory characteristics of the patients cohort are
given in Table 1. In particular, the duration of ERT, cre-
atinine blood concentrations and presence or absence of
LGE are documented at the time of investigation. Since
Fabry disease is known to affect the kidneys, among
others, serum creatinine values and glomerular filtration
rates of all patients are listed at the time of examination.
Fig. 1 Illustration demonstrating the voxel position (white rectangle) in the interventricular septum on (a) short heart axis view and (b) four-chamber
view at end-systole
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16 patients complained of neurological symptoms, such
as acroparesthesia. Furthermore, one of these patients
(manifest Fabry cardiomyopathy, LGE positive) with pro-
longed history of the disease suffered a stroke at young
age. Mostly, blood pressure was within the norm (range
120/60–155/95 mmHg). However, one overweight LGE
positive female patient (BMI 37.7) presented with ele-
vated blood pressure of 178/88 mmHg.
Spectroscopic measurements
Myocardial lipid content was not significantly elevated
in Fabry disease (p = 0.225), although the lipid/water res-
onance ratio tended to be higher in Fabry patients (me-
dian 0.33 %; IQR 0.16–0.91 % [range 0.10–5.14 %];
mean ± standard error (SE) 0.93 ± 0.24 %), as compared
to the healthy control group (median 0.25 %; IQR 0.16–
0.42 % [range 0.10–2.28 %]; mean ± SE 0.44 ± 0.10 %)
(Fig. 3a). Four female Fabry patients presented with a
notable myocardial lipid content of > 3.0 % (3.29, 5.14,
4.05, 3.59 %; see Table 1 for detailed patients informa-
tion) whereas only two controls presented with myocar-
dial lipid content of slightly above 2.0 % (2.13 %, 2.28 %).
Parameters of cardiac function
Measurement of LV mass differed significantly in both
groups. Compared to the healthy control group (mean ±
SD; 127.6 ± 27.1 g), LV mass was significantly higher in
Fabry patients (mean ± SD; 159.3 ± 66.5 g); (p = 0.019)
(Fig. 5a). In contrast to LV mass parameters, EF was
similar in both groups (mean EF ± SD; 64.2 ± 8.6 % in
patients vs. 63.2 ± 6.5 % in controls) (p = 0.613).
Patients LGE positive – Patients LGE negative
In 20 out of 30 patients LGE was found in the basal
inferolateral section of the left ventricular wall (Fig. 4).
Spectroscopic measurements
Within the patients cohort the comparison of mean
lipid/water ratio in LGE negative and LGE positive Fabry
patients revealed similar myocardial lipid content in
both subgroups (median 0.29 %; IQR 0.15 – 0.90 %
[range 0.10–5.14 %]; mean ± SE 0.93 ± 0.32 % in LGEpos.
vs. median 0.49 %; IQR 0.21–1.12 % [range 0.10–
4.05 %]; mean ± SE 0.92 ± 0.36 % in LGEneg.) (Fig. 3b),
showing no significant difference (p = 0.509).
Parameters of cardiac function
Compared to LGE negative (n = 10) patients, we ob-
served a trend towards LV mass increase in LGE positive
(n = 20) Fabry patients (mean LV mass of 173.6 ± 68.9 g
in LGEpos. vs. 130.8 ± 54.2 g in LGEneg. patients) (Fig. 5b)
without statistical significance (p = 0.076). LV function
(expressed as EF) was similar in LGE positive and LGE
negative Fabry patients (mean EF ± SD; 65.5 ± 9.5 % in
LGEpos. vs. 61.7 ± 5.8 % in LGEneg.) (p = 0.188).
Discussion
Cardiac involvement in Fabry disease
With progress of the disease, almost all male Fabry pa-
tients develop symptoms of cardiac insufficiency due to
pathological alteration of cardiac morphology and
function [29]. Increase of myocardial mass and progres-
sive myocardial fibrosis are the hallmarks of cardiac in-
volvement in Fabry disease and can be detected in MR
imaging [7, 8, 30]. While the deposition of Globotriao-
sylceramide (Gb3) is ubiquitous in the myocardium,
LGE is typically restricted to the inferior basal parts of
the left ventricle [7].
Accordingly, 20 of our 30 patients presented LGE in
the inferolateral parts of the left ventricular wall, corre-
sponding with the typical localization of fibrosis in Fabry
Fig. 2 Non-suppressed spectra (a) show the typical peak of tissue water set to 4.7 ppm. Water supressed (b) single voxel spectroscopy
demonstrating lipid peaks in typical position (CH2 [methylene] group at 1.3 ppm; CH3 [methyl] group at 0.9 ppm). Note the different
scaling of the y-and x axis
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cardiomyopathy. One might argue that myocardial lipid
acquisition and, respectively, voxel placement should be
chosen in a position typical for LGE, improving the like-
lihood of acquiring even higher pathological lipid values.
Taking into account that patients suffering from Fabry
disease develop a global left ventricular hypertrophy in
late stages of the disease and ubiquitous deposition of
sphingolipids in the myocardium of patients suffering
from cardiac Fabry disease is described in literature, we
assume a change of lipid concentration spread over the
whole myocardium. There is an appealing advantage of
voxel placement in the interventricular septum: there is
only a minor or even zero risk to acquire false positive
results deriving from lipid contamination of the voxel by
epicardial fat [25, 27, 31–36].
Because of the coexistence of advanced renal dis-
ease in Fabry patients, which sometimes precludes
the use of a contrast agent, retention parameters
(glomerular filtration rate, serum creatinine) were
collected from all patients. Furthermore most of the
patients had normal blood pressure values. Only one
female presented with an elevated blood pressure of
178/88 mmHg. Possible explanations might be the
patient suffering from Fabry cardiomyopathy (LGE
positive; elevated LV mass), or her advanced obesity
(BMI 37.7).















EF [%] LVM [g] LGE lipids [%] NS
1 49 f 33.8 140 100 0 113 0.6 55 92 y 0.27 n
2 43 f 20.6 125 60 0 116 0.6 64 127 y 3.29 y
3 17 m 20.0 138 73 1 156 0.7 56 131 n 0.15 y
4 52 f 23.5 170 70 7 82 0.8 70 197 y 5.14 y
5 23 m 29.2 120 78 4 127 0.8 64 217 n 1.76 n
6 43 m 28.7 125 83 9 47 1.7 71 207 y 0.10 y
7 50 f 23.3 104 69 3 70 0.9 78 161 y 0.14 n
8 37 f 27.3 115 85 0 120 0.6 59 104 n 0.30 n
9 51 f 21.6 101 74 3.5 80 0.8 69 78 y 1.36 n
10 19 m 20.2 108 88 3.5 116 0.9 53 129 n 0.61 n
11 27 f 20.5 115 80 0 91 0.8 65 88 n 4.05 n
12 50 f 37.7 178 88 9 94 0.7 79 189 y 0.92 y
13 52 f 38.7 145 95 9 93 0.7 83 175 y 0.85 y
14 43 m 19.2 120 70 10 47 1.7 60 227 y 0.54 y
15 53 f 22.8 120 80 4 76 0.8 73 132 y 0.22 n
16 50 m 17.5 110 80 7 95 0.9 69 253 y 0.30 y
17 42 m 26.9 140 85 7 95 0.9 47 386 y 0.24 y
18 48 f 23.1 110 75 0 86 0.8 69 192 n 0.23 n
19 17 f 19.4 108 76 0 — 0.8 56 83 y 3.59 n
20 68 f 19.8 115 80 0 82 0.7 66 84 n 0.90 y
21 46 m 25.4 129 70 9 69 1.2 65 226 y 0.14 y
22 28 m 31.0 115 65 6 158 0.6 57 155 y 0.10 y
23 50 f 27.2 112 104 0 71 0.9 68 141 y 0.57 n
24 30 m 24.3 135 90 4 112 0.9 69 176 y 0.45 y
25 42 m 21.0 155 95 6 96 0.9 52 179 y 0.10 y
26 22 f 19.3 116 67 0 111 0.7 69 73 n 0.10 n
27 61 f 18.9 140 66 0 77 0.8 61 87 n 0.70 y
28 51 f 21.4 91 69 0 70 0.9 69 140 y 0.18 n
29 51 f 28.4 145 95 0 69 0.9 56 148 y 0.16 y
30 28 m 24.2 133 70 9 90 1.0 55 203 n 0.36 n
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, ERT treatment with enzyme replacement therapy, GFR glomerular filtration rate,
Crea serum creatinine concentration, EF ejection fraction, LVM left ventricular mass, LGE late enhancement, NS neurological symptoms
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Cardiac 1H-MRS
Although we are aware that methylene (CH2) and me-
thyl (CH3) groups do not represent the total myocardial
lipid content, we limited our measurements to these two
peaks in accordance with previous studies [17, 25]. The
mean lipid/water resonance ratio of 0.44 ± 0.09 % de-
tected in healthy subjects is in accordance with previ-
ously published data ranging from 0.38 ± 0.02–0.52 ±
0.11 % [17, 25, 37].
Our results show no significant difference between
myocardial lipid content in Fabry patients and healthy
controls (p = 0.225). For the majority of Fabry patients
there was no evidence that lysosomal storage of sphingo-
lipids influences cardiac lipid content as measured by
1H-MRS. However, we found noticeably elevated myo-
cardial lipid content in a small number of female Fabry
patients (4 patients [3 LGE positive] with a lipid/water
resonance ratio > 3 %), which raises the question of po-
tential gender effects. The average cardiac lipid content
found in our Fabry cohort is not in line with former
study results by Thompson et al. postulating elevated
cardiac lipid content in a relatively small cohort of n = 4
Fabry patients [13]. Furthermore, a previous study of
Fabry disease from our own research group measures
myocardial lipid elevation only in one patient presenting
with advanced Fabry cardiomyopathy, whereas the aver-
age number of Fabry patients in this study presented
with normal lipid-to-water-ratio [17].
Conceivable explanations for higher cardiac lipid
content measured in a few subjects from the Fabry
cohort may be firstly an applied ERT for an extended
time period (mostly between 4 and 10 years; select
patients between 1 and 3.5 years), indicating a pro-
longed disease history. On the other hand, the poten-
tial of ERT to affect myocardial lipid content has not
been addressed in literature. Secondly, the published
cohort gender proportion is imbalanced towards fe-
males (12 male, 18 female). Consequently, a necessary
consideration includes the lack of correlation of loss
of myocardial function and fibrosis with myocardial
hypertrophy among females as opposed to males [4].
Furthermore, gender specific relative elevation of
myocardial lipid content in females has been eluci-
dated in the past [38], an assumption which could
possibly influence our findings.
Fig. 3 Boxplots demonstrate that myocardial lipid content was not significantly elevated in Fabry disease (p = 0.225). Nevertheless four Fabry
patients presented with a notable myocardial lipid content of > 3.0 % (a). Within the patient cohort myocardial lipid content is similar in late
gadolinium enhancement (LGE) positive and LGE negative Fabry patients (p = 0.509) (b)
Fig. 4 Late gadolinium enhancement (LGE) in the typical position
for Fabry disease in the inferolateral parts of the left ventricle
(arrows) of a 43 year-old male patient
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The subgroup evaluation of LGE positive and LGE
negative patients within the Fabry cohort revealed a
trend towards elevated LV mass in LGE positive patients
(p = 0.076). When evaluating LGE positive and negative
subgroups within the Fabry cohort, no correlation
between the presence of LGE (typically occurring in the
lateral wall) and septal lipid concentration measured by
1H-MRS was observed. Our results suggest that
there are at least two different underlying pathome-
chanisms in Fabry cardiomyopathy. Time line devel-
opment of fibrosis and elevated myocardial lipid
content occurring in some individuals seems unpre-
dictable at this time, possibly due to differences in
underlying pathomechanisms.
Most studies concerning ERT in Fabry disease demon-
strate a decelerated development of disease after early
ERT onset. Therefore early detection of myocardial
changes is from utmost importance. Including the re-
sults of Sado et al., who suggested myocardial T1 values
as a marker of early cardiac involvement [14], a compre-
hensive cardiac examination including three subsections
(LGE; 1H-MRS; T1 mapping) could hold the highest po-
tential for the final assessment of early and late myocar-
dial changes, including the potential role of lipid
accumulation in cardiac Fabry disease.
Limitations
Due to the known risks of myocardial biopsy, we did not
perform comparative invasive triglyceride measure-
ments. Previously published data by O´Connor et al.
demonstrated a remarkably high correlation coefficient
between in vivo (1H-MRS) and ex vivo triglyceride
measurements [21]. The results of that study suggest
that triglyceride quantification by MRS is suitable for
clinical routine studies.
At the time of examination 18 patients were treated
with ERT, while 12 patients did not receive ERT. The in-
fluence of ERT on myocardial lipid content remains un-
clear to date. A separate statistical evaluation of patient
subgroups with and without ERT was not performed
within this study cohort due to sample size. Neverthe-
less, long-term monitoring of myocardial lipids using
1H-MRS to explore the effects of ERT represents an in-
teresting field for larger future studies.
We did not apply intravenous contrast medium to our
control group, while this was used in the patient cohort.
To ensure a short examination time and to avoid an arti-
ficial prolongation of the investigation, the time slot be-
tween i.v. contrast application and LGE acquisition was
used for the spectroscopic measurements in our pa-
tients. One must be aware that gadolinium-based con-
trast agents potentially increase the water peak area, as
well as selected metabolite peaks (e.g. choline), especially
when using short echo times [39]. Particularly these ob-
servations are described in breast cancer as well as brain
tumors [40–43]. However, best to our knowledge, there
is no published data showing an influence of gadolinium
based contrast agents on the results of lipid evaluation
in cardiac 1H-MRS. In the future, upcoming single
breath hold 1H-MRS sequences should enable time-
saving spectroscopic data acquisition in patients prior to
i.v. contrast administration [44].
Furthermore, mean age comparison between patients
and controls is not fully congruent. More importantly, in
Fig. 5 Left ventricular mass (LVM) is significantly elevated in Fabry disease (* p = 0.019) (a). Within the patient cohort LVM is tendentiously
higher in late gadolinium enhancement (LGE) positive Fabry patients (p = 0.076) compared to LGE negative patients (b). Error bars show
standard deviation
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the light of the knowledge that BMI correlates with
myocardial lipid content [37], the mean BMI of the two
cohorts shows a slight mismatch (mean BMI in patients
24.5 kg/m2 vs. 22.4 kg/m2 in controls; p = 0.079). We
cannot exclude any influence of the BMI on lipid levels
within our patients. Moreover, the gender proportion of
the patient cohort is imbalanced towards females (12
male vs. 18 female).
Owing to the x-linked inheritance of Fabry disease, a
separate evaluation of both genders will be necessary in
future studies. Due to the sample size this was not feas-
ible in the present study. Therefore, further larger stud-
ies will be needed to elucidate possible gender aspects.
Conclusions
The present study demonstrates the potential of lipid
metabolic investigation embedded in a comprehensive
examination of cardiac morphology and function in
Fabry disease. There was no evidence that lysosomal
storage of sphingolipids influences cardiac lipid content
as measured by 1H-MRS. Therefore the potential of 1H-
MRS as a tool for early diagnosis of cardiac involvement
and for optimization of ERT onset as leading therapy in
Fabry disease remains questionable and needs to be fur-
ther evaluated. In future native T1 mapping might be a
superior comparator to validate actual changes in the
myocardium. Finally, the authors share the opinion that
a comprehensive cardiac examination including three
subsections (LGE; 1H-MRS; T1 mapping), could hold the
highest potential for the final assessment of early and
late myocardial changes in Fabry disease.
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